England & Company served as joint financial advisor with Goodbody Stockbrokers UC to Collagen Solutions Plc (LON: COS) in its sale to Rosen's Diversified, Inc ("RDI") for 6.50 pence per share, representing an enterprise value of £31.6 million ($41 million), equating to approximately 7.8x FY2020 revenues.
Collagen Solutions, headquartered in Glasgow, Scotland, is a leading contract developer and manufacturer of regenerative medical devices using collagen and tissue-based biomaterials, as well as a supplier of these materials. These products are used in a wide variety of applications including orthopedics, cardiovascular, dental, wound healing and neurology.
Commenting on the transaction, Jamal Rushdy, Chief Executive Officer of Collagen Solutions, said: "We have made tremendous progress in our vision to Be the Industry's First Choice for Regenerative Biomaterials. Being part of RDI will generate significant growth opportunities and create enhanced value to the benefit of all stakeholders and in particular our employees, customers and suppliers."
"We are very pleased to have partnered with England & Company and Goodbody Stockbrokers for this transaction," Rushdy continued. "The combined England and Goodbody team was key in advising the Company on various potential courses of action and navigating the sale process. The acquisition by RDI will help Collagen Solutions continue to grow, innovate, and expand its markets."
RDI is a multi-billion dollar, family-owned and controlled business, headquartered in Fairmont, Minnesota. RDI sells a broad range of food, agricultural and scientific products into more than 30 countries, across five continents, and has over 4,500 employees. Collagen Solutions will become part of RDI's life sciences division, which includes Scientific Life Solutions ("SLS"), a supplier of critical components to the bioresearch and biomedical fields.